Uhlmann Group Spins Off visiotec GmbH - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Uhlmann Group Spins Off visiotec GmbH


An independent subsidiary of Uhlmann Germany, visiotec GmbH, was created on April 1, 2013 to focus on inspection, monitoring, and control systems for automated pharmaceutical manufacturing processes, the company announced in a press release.

The spin-off addresses the pharmaceutical industry’s demand for a more holistic approach beyond the traditional borders of manufacturing and packaging, said the company. Visiotec will provide solutions for product quality and safety using inline monitoring, based on its expertise in process analytical technologies, such as high-speed, near-infrared analysis and advanced mass-verification technology.

Visiotec GmbH will operate globally from offices in Germany, Switzerland, and the United States. The printing, inspection, and track-and-trace products formerly offered by Uhlmann VisioTec GmbH for packaging applications will be handled by the Uhlmann Group’s dedicated Uhlmann Customer Services division.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here